SCHEMBL20322985

SCHEMBL20322985

CSNC(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TAS1R3 Q7RTX0 3/20 0.47
TAS1R1 Q7RTX1 3/20 0.47
TAS1R2 Q8TE23 3/20 0.47
TYK2 P29597 2/20 0.47
HPGD P15428 1/20 0.47
JAK2 O60674 1/20 0.47
CYP3A4 P08684 1/20 0.47
JAK1 P23458 1/20 0.47
RAB9A P51151 1/20 0.45
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
APAF1 O14727 1/20 0.44
TDP2 O95551 1/20 0.44
NSD2 O96028 1/20 0.44
ABL1 P00519 1/20 0.44
MAPT P10636 1/20 0.44
GALK1 P51570 1/20 0.44
BLM P54132 1/20 0.44
RIN1 Q13671 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19523026 0.88 GAA (0.58) TYK2HPGDJAK2CYP3A4JAK1
SCHEMBL19523019 0.87 TYK2 (0.57) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL9350186 0.85 PPIA (0.50) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL7218036 0.85 RAB9A (0.41) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL4157657 0.77 DOT1L (0.56) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL19523015 0.76 MEN1 (0.50) ALDH1A1TYK2HPGDJAK2JAK1
SCHEMBL19541876 0.76 HPGD (0.56) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL20051730 0.74 TYK2 (0.42) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL11005407 0.74 ALDH1A1 (0.56) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2
SCHEMBL8857056 0.73 GAA (0.53) ALDH1A1TAS1R3TAS1R1TAS1R2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208061-B2 Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-02-19 US disclosed
US-20180179224-A1 Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179224-A1 Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease RORA, RORC, RORB ALDH1A1 224/4885TAS1R3 2084/4885TAS1R1 1778/4885
US-10208061-B2 Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORA, RORB ALDH1A1 322/4885TAS1R3 1282/4885TAS1R1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.